Skip to content
ESPT
MARKETS / BALCAO / Health care / Pharmaceuticals / MCUJF
BALCAO · PHARMACEUTICAL PREPARATIONS · SMALL CAP

Medicure Inc. MCUJF

10 fiscal years on record · CAD · FY2024 reported · SEC filings only
CAD 21.9M
▲ 1.0% YoY
CAD -1.0M
CAD 638,000
▼ 64.7% YoY

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

In brief

What this company does

Medicure is a company focused on the development and commercialization of pharmaceuticals and healthcare products for patients and prescribers in the United States market and sales to the Retail Public of pharmaceutical products. On December 22, 1999, the Company was formed by the amalgamation of Medicure Inc. with Lariat Capital Inc. pursuant to the provisions of the Business Corporations Act (Alberta). ZYPITAMAG® contributed revenue of $6.5 million ($2.8 million through the traditional insured channels, and an additional $3.7 million through Marley Drug) to the Company for the year ended December 31, 2025, an increase from the prior year, where ZYPITAMAG® provided total revenue of $6.2 million ($3 million through the traditional insured channels, and an additional $3.2 million through Marley Drug) to the Company during the year ended December 31, 2024. As at December 31, 2025, the Company had use of approximately 10,500 square feet.

Written from the business description in Medicure Inc.'s annual report to the U.S. Securities and Exchange Commission, filed 24 April 2026. Every sentence was checked against that document before publication.

Growth

CAD 21.9M
Revenue, FY2024 · full 10-year series below
Revenue CAD M Net income CAD M
FY2024 · Revenue 21.9 · Net income -1.0
20M40M-10M-20M
2015201820212024
Compound annual growth
+0.2%
+1.7%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at +1.7% a year over the five years to FY2024.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability

−5 cents
lost on every revenue dollar
Operating margin Net margin
FY2024 · Operating · · Net -4.7%
50%100%150%-50%
201520192024
ROE
FY2024 · ROE -5.1%
50%100%-10%-20%-30%
201520192024
Three returns, three denominators.
Return on capital employedNot available: we don't have a clean operating profit figure for this period.
Gross margin59.7%
Operating margin·
Net margin-4.7%
EBITDA·

Each CAD of equity lost 5 cents this year.

Cash & shareholders

·
returned in FY2024 · dividends + net buybacks
Free cash flow CAD M
FY2024 · FCF 0.6
10M20M-10M-20M
201520192024
Net buybacks CAD M Dividends CAD M
FY2022 · Dividends · · Net buybacks 0.0
2M3M
2018201920202022
Dividends paid·
Net buybacks·
Share of profit·
Consecutive raises·

Total assetsCAD 29.7M
CashCAD 7.2M
Current ratio1.89×

Not available: we don't have the total debt figure for this period.

The 10-year record

10 fiscal years
Every figure from documents filed with the SEC · CAD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative—not applicable◌not available in our data
MCUJF, 10-year financial record
Metric 2024202320222021202020192018201720162015
Revenue CAD B0.00.00.00.00.00.00.00.00.00.0
Operating income CAD B◌◌◌◌◌◌−0.00.00.00.0
EBITDA CAD B◌◌◌◌◌◌−0.00.0◌◌
Income tax CAD B−0.0−0.0−0.00.00.00.00.0−0.00.00.0
Net income CAD B−0.0−0.00.0−0.0−0.0−0.00.00.00.00.0
Free cash flow CAD B0.00.00.00.0◌−0.0−0.00.0◌◌
EPS, diluted CAD −0.10−0.090.13−0.07−0.64−1.320.242.391.560.11
Dividend / sh CAD ◌◌◌◌◌◌◌◌◌◌
Payout % — not applicable: no dividend——————————
ROE %−5.1−4.56.9−3.9−29.7−35.84.874.3132.737.4

Slide the table for earlier years. "—" not applicable · "◌" not available in our data.

Compare

This company against its peers

Medicure Inc.vsMindWalk Holdings Corp.Same industry: Pharmaceutical PreparationsMedicure Inc.vsAdastra Holdings Ltd.Same industry: Pharmaceutical PreparationsMedicure Inc.vsAvricore Health Inc.Same industry: Pharmaceutical PreparationsMedicure Inc.vsOrganigram Global Inc.Same industry: Pharmaceutical PreparationsMedicure Inc.vsPyroGenesis Canada Inc.Same industry: Pharmaceutical Preparations
More in this sector

Other companies filing in the same sector

MCK · COR · CAH · JNJ · HCA · LLY
Provenance

Company facts, as filed

How we verify · 0 failures · 1 divergence in 48 reconciliationsAUDITED

Reconciled in 9 of the 10 fiscal years we could check. 1 of those reconciliations are divergences — the figures exist but don't fit the formula this check expects; that isn't the same as an error. 18 checks were skipped: the balance sheet is not tagged before 2016. Eight checks were skipped: EPS is not tagged before 2015. Eight checks were skipped: revenue is not tagged before 2015.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidityCurrency consistency0 failures1 divergent
ActivityPharmaceutical Preparations
Listed onOTC market
Incorporated inoutside the United States — SEC code A2
Fiscal year endsDecember 31
Data on record since2015

Share this section

Download image